Cyclophosphamide as disease-modifying therapy for scleroderma: Pros and cons

International Journal of Clinical Rheumatology

Volumn 6, Issue 2, 2011, Pages 219-230

  Chighizola, Cecilia ^a   Ong, Voon H ^b   Denton, Christopher P ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

cyclophosphamide; hemorrhagic cystitis; interstitial lung disease; malignancy; systemic sclerosis

Indexed keywords

ACROLEIN; ANTIEMETIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CENTROMERE ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DNA DIRECTED RNA POLYMERASE; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE INHIBITOR; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; MESNA; METHYLPREDNISOLONE; PHOSPHORAMIDE MUSTARD; PLACEBO; PREDNISOLONE;

ANGIOSARCOMA; BLADDER CANCER; BLADDER CARCINOMA; BONE MARROW TRANSPLANTATION; CHEMICAL STRUCTURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DEGRADATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TARGETING; DRUG URINE LEVEL; EVENT FREE SURVIVAL; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LEUKEMIA; LEUKOPENIA; LOW DRUG DOSE; LUNG CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; MONOTHERAPY; MYOCARDITIS; OUTCOME ASSESSMENT; PATHOGENESIS; PLASMAPHERESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOMA; SCLERODERMA; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT TUMOR; VULVA CARCINOMA;

EID: 79955066247     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.10.112     Document Type: Review

References (72)

1. Bryan C, Knight C, Black CM, Silman AJ: Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum. 42(12), 2660-2665 (1999). (Pubitemid 30327188)
2. Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP: Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 103(2), 109-115 (2010).
3. Ong VH, Denton CP: Innovative therapies for systemic sclerosis. Curr. Opin. Rheumatol. 22(3), 264-272 (2010).
4. Becker H, Potyka P, Weber C, Renelt M, Federlin K: T-helper cell subsets in patients with inflammatory rheumatic diseases undergoing immunosuppressive therapy. Immun. Infekt. 19(1), 26-27 (1991).
5. Steen VD, Medsger TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis. 66(7), 940-944 (2007). (Pubitemid 46999798)
6. Hoyles RK, Khan K, Shiwen X et al.: Fibroblast-specific perturbation of transforming growth factor b signalling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum. 58(4), 1175-1188 (2008). (Pubitemid 351564021)
7. Konigshoff M, Kramer M, Balsara N et al.: WNT1-inducible signalling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J. Clin. Invest. 119, 772-787 (2009).
8. Mathai SK, Gulati M, Peng X et al.: Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab. Invest. 90, 812-823 (2010).
9. Kim KK, Wei Y, Szekeres C et al.: Epithelial cell a3b1 integrin links b catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J. Clin. Invest. 119, 213-224 (2009).
10. Ferri C, Valentini G, Cozzi F et al.: Systemic sclerosis: demographic, clinical, and serological features and survival in 1012 Italian patients. Medicine 81, 139-153 (2002). (Pubitemid 34218569)
11. Nihtyanova SI, Denton CP: Autoantibodies as predictive tools in systemic sclerosis. Nat. Rev. Rheumatol. 6(2), 112-116 (2010).
12. Steen VD, Conte C, Owens GR, Medsger TA: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 37(9), 1283-1289 (1994). (Pubitemid 24320744)
13. Bouros D, Wells AU, Nicholson AG et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 165(12), 1581-1586 (2002). (Pubitemid 34693935)
14. Tashkin DP, Elashoff R, Clements PJ et al.: Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 176(10), 1026-1034 (2007). (Pubitemid 350127847)
15. Goh NS, Desai SR, Veeraraghavan S et al.: Interstitial lung disease in systemic sclerosis - a simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248-1254 (2008). (Pubitemid 351860934)
16. Kim HG, Tashkin DP, Clements PJ et al.: A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin. Exp. Rheumatol. 28, S26-S35 (2010)
17. White B, Moore WC, Wigley FM, Xiao H, Wise R: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Intern. Med. 132(12), 947-954 (2000). (Pubitemid 30397594)
18. Domiciano D, Bonfá E, Borges CT et al.: A long-term prospective randomized controlled study on non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin. Rheumatol. 30(2), 223-229 (2011).
19. Wanchu A, Suryanaryana B, Sharma S, Sharma A, Bamberry P: High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int. J. Rheum. Dis. 12(3), 239-242 (2009).
20. Simeon-Aznar C, Follonosa-Pla V, Tolosa-Vilella C et al.: Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir. Med. J. 2, 39-45 (2008).
21. Berezne A, Ranque B, Valeyre D et al.: Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J. Rheumatol. 35(6), 1064-1072 (2008). (Pubitemid 351813153)
22. Beretta L, Caronni M, Raimondi M et al.: Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin. Rheum. 26(2), 168-172 (2007). (Pubitemid 46020237)
23. Yiannopoulos G, Pastromas V, Antonopoulos V et al.: Combinationof intravenous cyclophosphamide and methylprednisolone in patients with 634 systemic sclerosis and interstitial lung disease Rheumatol. Int. 27(4), 357-361 (2007). (Pubitemid 46122279)
24. Valentini G, Paone C, La Montagnana G et al.: Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients withearly diffuse disease. Scand. J. Rheumatol. 35(1), 35-38 (2006). (Pubitemid 43247252)
25. Ostojic P, Damianov N: Improvement of lung function in patients with systemic sclerosis after six months of cyclophosphamide pulse therapy. Clin. Rheumatol. 25(6), 819-821 (2006). (Pubitemid 44473145)
26. Airò P, Danieli E, Parrinello G et al.: Intravenous cyclophosphamide therapy for systemic sclerosis. A single center experience and review of literature with pooled analysis of lung function test results. Clin. Exp. Rheumatol. 22(5), 573-578 (2004). (Pubitemid 39302934)
27. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P: Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J. Rheumatol. 29(11), 2371-2378 (2002). (Pubitemid 35266028)
28. Giacomelli R, Valentini G, Salsano F et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J. Rheumatol. 29(4), 731-736 (2002). (Pubitemid 34303867)
29. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J. Rheumatol. 29(2), 298-304 (2002). (Pubitemid 34118777)
30. Davas E, Peppas C, Maragou M, Alvanou E, Hondros D, Dantic P: Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with lung scleroderma. Clin. Rheumatol. 18(6), 455-461 (1999). (Pubitemid 30014164)
31. Varai G, Earle l, Jimenez S, Steiner R, Varga J: A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J. Rheumatol. 25, 1325-9 (1998). (Pubitemid 28312350)
32. Akesson A, Scheja A, Lundin A, Wollheim FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 37(5), 729-735 (1994). (Pubitemid 24145078)
33. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C: Cyclophosphamide and low dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J. Rheumatol. 20, 838-844 (1993). (Pubitemid 23158478)
34. Tashkin DP, Elashoff R, Clements PJ et al.: Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354(25), 655-666 (2006).
35. Goldin J, Elashoff R, Kim HJ et al.: Treatment of scleroderma- interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 136(5), 1333-1340 (2009).
36. Hoyles R, Ellis RW, Wellsbury J et al.: A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 12, 3962-3970 (2006). (Pubitemid 44955900)
37. Seibold JR, Denton CP, Furst DE et al.: Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 62(7), 2101-2108 (2010)
38. Nannini C, West CP, Erwin PJ, Matteson EL: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res. Ther. 10(5), R124 (2008).
39. Broad K, Pope JE: The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med. Sci. Monit. 16(9), RA187-RA190 (2010).
40. Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH: Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med. Decis. Making 28(6), 926-937 (2008).
41. Teare JP, Sherman D, Greenfield SM et al.: Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 342, 895-898 (1993). (Pubitemid 23291593)
42. Scheja A, Akesson A, Horslev-Petersen K: Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. Scand. J. Rheumatol. 21, 5-9 (1992).
43. Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, Kuwana M: Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheumatology (Oxford) 49(12), 2375-2380 (2010).
44. Zampetaki A, Kirton JP, Xu Q: Vascular repair by endothelial progenitor cells. Cardiovasc. Res. 78(3), 413-421 (2008). (Pubitemid 351769775)
45. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M: Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130, 182-189 (2006). (Pubitemid 44116858)
46. Trad S, Amoura Z, Beigelman C et al.: Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 54(1), 184-191 (2006). (Pubitemid 43122201)
47. Farge D, Labopin M, Tyndall A et al.: Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience for the European group for blood and marrow transplantation working party on autoimmune diseases. Haematologica 95(2), 284-292 (2010).
48. Vonk MC, Marjanovic Z, van den Hoogen FH et al.: Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann. Rheum. Dis. 67, 98-104 (2008).
49. Verrecchia F, Laboureau J, Verola O et al.: Skin involvement in scleroderma: where histological and clinical scores meet. Rheumatology (Oxford) 46, 833-841 (2007). (Pubitemid 47061718)
50. Nash RA, McSweeney PA, Crofford LJ et al.: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110, 1388-1396 (2007). (Pubitemid 47281441)
51. Fleming JN, Nash RA, McLeod DO et al.: Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3, e1452 (2008).
52. Aschwanden M, Daikeler T, Jaeger KA et al.: Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann. Rheum. Dis. 67, 1057-1059 (2008). (Pubitemid 351956684)
53. Dau PC, Kahaleh MB, Sagebiel RW: Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum. 24(9), 1128-1136 (1981). (Pubitemid 11057339)
54. Nadashkevich O, Davis P, Fritzler M, Kovalenko W: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin. Rheumatol. 25(2), 205-212 (2006). (Pubitemid 43372319)
55. Khanna D, Furst DE, Hays RD et al.: Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study. Ann. Rheum. Dis. 10, 1325-1329 (2006). (Pubitemid 44620441)
56. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB et al.: Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med. 118, 2-10 (2005). (Pubitemid 40082450)
57. Perera A, Fertig N, Lucas M et al.: Clinical subsets, skin thiockness progression rate and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum. 56, 2740-2746 (2007). (Pubitemid 47237293)
58. Czirják L, Kumánovics G, Varjú C et al.: Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann. Rheum. Dis. 67(1), 59-63 (2008).
59. Meune C, Vignaux O, Kahan A, Allanore Y: Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch. Cardiovasc. Dis. 103, 46-52 (2010).
60. Carette S, Turcotte J, Mathon G: Severe myositis and myocarditis in SSc. J. Rheumatol. 12(5), 997-999 (1985).
61. Liangos O, Neure l, Kuhul U et al.: The possible role of myocardial biopsy in systemic sclerosis. Rheumatology (Oxford) 39, 674-679 (2000). (Pubitemid 30459955)
62. Stack J, McLaughlin P, Sinnot C et al.: Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone. Scand. J. Rheumatol. 39(4), 349-350 (2010).
63. Allanore Y, Vignaux O, Arnaud L et al.: Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Ann. Rheum. Dis. 65(2), 249-252 (2006). (Pubitemid 43132003)
64. Al-mashaleh M, Bak H, Moore J et al.: Resolution of sclerodermatous myocarditis after autologous stem cell transplantation. Ann. Rheum. Dis. 65(9), 1247-1248 (2006). (Pubitemid 44277409)
65. Schulz SW, O'Brien M, Maqsood M et al.: Improvement of severe systemic sclerosis-associated gastric antral vascular ectasia following immunosuppressive treatment with intravenous cyclophosphamide. J. Rheumatol. 36(8), 1653-1656 (2009).
66. Lorenzi AR, Johnson AH, Davies G, Gough A: Gastric antral vascular ectasia in systemic sclerosis: complete resolution with methylprednisolone and cyclophosphamide. Ann. Rheum. Dis. 60(8), 796-798 (2001). (Pubitemid 32685882)
67. Jais X, Launay D, Yaici A et al.: Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 58(2), 521-531 (2008). (Pubitemid 351294886)
68. Radis CD, Kahl LE, Baker GL et al.: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 38(8), 1120-1127 (1995).
69. Reinhold-Keller E, Kekow J, Schnabel A et al.: Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 37, 919-924 (1994). (Pubitemid 24184546)
70. Shah AA, Rosen A, Hummers L et al.: Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 62(9), 2787-2795 (2010).
71. Monach PA, Arnold LM, Merkel PA: Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic disease. Arthritis Rheum. 62(1), 9-21 (2010).
72. McCune WJ, Fox DA: Immunosuppressive agents: biologic effects in vivo and in vitro. In:Lupus: Molecular and Cellular Pathogenesis. Kammer GM, Tsokos GC (Eds).Humana Press, Totowa, NJ, USA, 612-641 (1999).